AstraZeneca’s SERD pill overcomes adcomm defeat to win FDA nod in breast cancer

The approval opens up a “modest” market for AstraZeneca’s Etcamah, according to Leerink analysts, who nevertheless looked forward to an upcoming late-stage readout that could lead to a “significantly larger opportunity” for the drug.